Onward Med NV (ONWRY)
OQX
Price as at 30 Sept 2026, 22:45 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Onward Med NV trades at $3.03, which is 61% above the $1.18 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 41 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
About Onward Med NV
Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with spinal cord injury (SCI) in the United States, Europe, and internationally. The company offers ARCEX System, an external stimulator that is intended to improve hand strength and sensation following SCI; ARCIM System, an implantable system currently used to explore potential indications in clinical feasibility studies; ARCBCI System, an implantable system currently being investigated to enable thought driven movement of the legs and upper extremities. Onward Medical N.V. was founded in 2014 and is headquartered in Eindhoven, Netherlands.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
ONWRY passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Common questions
Is Onward Med NV (ONWRY) undervalued?
Against our fair value estimate of $1.18, ONWRY at $3.03 is 61% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Where does SteadyShares get its ONWRY data?
Fundamentals for ONWRY come from company filings and exchange data, as listed on OQX; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 22:45 UTC and is delayed. Our data quality score for this company is 71/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for ONWRY, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.